Literature DB >> 26592352

Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths.

Nick Sheron1.   

Abstract

In the World Health Organisation European Region, more than 2,370,000 years of life are lost from liver disease before the age of 50; more than lung cancer, trachea, bronchus, oesophageal, stomach, colon, rectum and pancreatic cancer combined. Between 60-80% of these deaths are alcohol related, a disease for which no pharmaceutical therapy has yet been shown to improve long-term survival. The toxicity of alcohol is dose related at an individual level, and is dose related at a population level; overall liver mortality is largely determined by population alcohol consumption. Trends in alcohol consumption correlate closely with trends in overall liver mortality, with 3-5-fold decreases or increases in liver mortality in different European countries over the last few decades. The evidence base for alcohol control measures aimed at reducing population alcohol consumption has been subjected to rigorous evaluation; most recently by the Organisation for Economic Co-Operation and Development (OECD). Effective alcohol policy measures reduce alcohol mortality, including mortality from liver disease. The most effective and cost effective measures have been summarised by the OECD and the World Health Organisation: regular incremental above inflation tax increases, a minimum price for alcohol, effective protection of children from alcohol marketing and low level interventions from clinicians. Simple, cheap and effective changes to alcohol policy by European Institutions and member states have the potential to dramatically reduce liver mortality in Europe.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Alcohol; Policy; Public health

Mesh:

Year:  2015        PMID: 26592352     DOI: 10.1016/j.jhep.2015.11.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  25 in total

Review 1.  Surveillance for hepatocellular cancer.

Authors:  Anna Roskilly; Ian A Rowe
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

Review 2.  Targeting Nrf-2 is a promising intervention approach for the prevention of ethanol-induced liver disease.

Authors:  Ning Zhao; Fang-Fang Guo; Ke-Qin Xie; Tao Zeng
Journal:  Cell Mol Life Sci       Date:  2018-06-11       Impact factor: 9.261

Review 3.  Epidemiological and etiological variations in hepatocellular carcinoma.

Authors:  Evangelista Sagnelli; Margherita Macera; Antonio Russo; Nicola Coppola; Caterina Sagnelli
Journal:  Infection       Date:  2019-07-25       Impact factor: 3.553

Review 4.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

Review 5.  Alcoholic liver disease.

Authors:  Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto
Journal:  Nat Rev Dis Primers       Date:  2018-08-16       Impact factor: 52.329

6.  ACG Clinical Guideline: Alcoholic Liver Disease.

Authors:  Ashwani K Singal; Ramon Bataller; Joseph Ahn; Patrick S Kamath; Vijay H Shah
Journal:  Am J Gastroenterol       Date:  2018-01-16       Impact factor: 10.864

7.  Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population.

Authors:  Justin Knox; Melanie Wall; Katie Witkiewitz; Henry R Kranzler; Daniel Falk; Raye Litten; Karl Mann; Stephanie S O'Malley; Jennifer Scodes; Raymond Anton; Deborah S Hasin
Journal:  Alcohol Clin Exp Res       Date:  2018-10-03       Impact factor: 3.455

Review 8.  A mini-review of the rodent models for alcoholic liver disease: shortcomings, application, and future prospects.

Authors:  Shi-Xuan Liu; Yan-Chao Du; Tao Zeng
Journal:  Toxicol Res (Camb)       Date:  2021-05-10       Impact factor: 3.524

Review 9.  Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.

Authors:  Szu-Yi Liu; I-Ting Tsai; Yin-Chou Hsu
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

10.  Clinical characteristics of sarcopenia in patients with alcoholic liver cirrhosis.

Authors:  Chisato Saeki; Tomoya Kanai; Masanori Nakano; Tsunekazu Oikawa; Yuichi Torisu; Masayuki Saruta; Akihito Tsubota
Journal:  JGH Open       Date:  2021-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.